<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00509145</url>
  </required_header>
  <id_info>
    <org_study_id>MS-LAQ-301</org_study_id>
    <secondary_id>EUDRACT 2007-003226-19</secondary_id>
    <nct_id>NCT00509145</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS)</brief_title>
  <acronym>ALLEGRO</acronym>
  <official_title>A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study, to Evaluate the Safety, Tolerability and Efficacy of Daily Oral Administration of Laquinimod 0.6 mg in Subjects With RRMS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Branded Pharmaceutical Products R&amp;D, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Branded Pharmaceutical Products R&amp;D, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Determination the efficacy of daily oral treatment with laquinimod 0.6 mg capsules as&#xD;
      compared to placebo in subjects with Relapsing Remitting Multiple Sclerosis (RRMS).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 13, 2007</start_date>
  <completion_date type="Actual">November 8, 2010</completion_date>
  <primary_completion_date type="Actual">November 8, 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relapse Rate: Number of Confirmed Relapses During the Double Blind Study Period</measure>
    <time_frame>Up to Month 24</time_frame>
    <description>A relapse was defined as the appearance of at least one new neurological abnormality or the reappearance of at least one previously observed neurological abnormalities lasting greater than or equal to 48 hours and immediately preceded by an improving neurological state of greater than or equal to 30 days from onset of previous relapse. An event was counted as a relapse only when the participant's symptoms were accompanied by observed objective neurological changes, consistent with one or more of the following: An increase of greater than or equal to 0.5 in the Expanded Disability Status Scale (EDSS) score as compared to previous evaluation, an increase of one grade in the actual score of greater than or equal to 2 of the 7 functional systems (FS), as compared to previous evaluation, or an increase of 2 grades in the actual score of one FS as compared to the previous evaluation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite Endpoint: Sum of the Number of T1 Gadolinium (Gd)-Enhanced Lesions on T1-Weighted MRI Images</measure>
    <time_frame>Month 12, Month 24</time_frame>
    <description>Composite score was calculated as the sum of the number of gadolinium (Gd)-enhanced lesions at Month 12 and the number of gadolinium (Gd)-enhanced lesions at Month 24 on T1-Weighted MRI scans.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Endpoint: Sum of the Number of New/Enlarging T2 Lesions</measure>
    <time_frame>Month 12, Month 24</time_frame>
    <description>Composite score calculated as the sum of T2 lesions at Months 12 and 24 that are new or enlarged.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation of Physical Disability Measured by the Time to Confirmed Progression of Expanded Disability Status Scale (EDSS)</measure>
    <time_frame>Baseline to Month 24</time_frame>
    <description>EDSS assesses disability in 8 functional systems with an overall score ranging from 0 (normal) to 10 (death due to multiple sclerosis [MS]). A confirmed progression of EDSS is defined as at least 1 point increase from baseline if baseline EDSS was between 0 and 5.0, or at least 0.5 point increase if baseline EDSS was 5.5 or higher, confirmed 3 months later. Participants were assessed between baseline and month 24 visit. Participants that met these criteria for any 3 consecutive months were counted in the progression category. Progression could not be confirmed during an MS relapse. Data is presented as a distribution of confirmed disease progression (CDP) events (number of participants with CDP).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Disability as Assessed by the Multiple Sclerosis Functional Composite (MSFC) Score</measure>
    <time_frame>Baseline, Month 24</time_frame>
    <description>The Multiple Sclerosis Functional Composite is an instrument assessing disability that consists of 3 clinical assessments. The 3 are Timed 25-Foot Walk, 9-Hole Peg Test which measures upper extremity (arm and hand) function, and PASAT (Paced Auditory Serial Addition Test) which is a measure of cognitive function that specifically assesses auditory information processing speed and flexibility, as well as calculation ability. A Z-score is used to define a common metric from the 3 assessments that constitute the MSFC score. The study's population at baseline was used as reference population for the Z-score calculation. A Z-score of 0 represents the population mean at baseline. Higher Z-scores correspond to an improved outcome.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1106</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Laquinimod</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Laquinimod 0.6 mg, oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Laquinimod</intervention_name>
    <description>Laquinimod 0.6 mg capsule, oral, once daily</description>
    <arm_group_label>Laquinimod</arm_group_label>
    <other_name>TV-5600</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral, once daily, capsule</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects must have a confirmed and documented MS diagnosis as defined by the Revised&#xD;
             McDonald criteria [Ann Neurol 2005: 58:840-846], with a relapsing-remitting disease&#xD;
             course.&#xD;
&#xD;
          2. Subjects must be ambulatory with converted Kurtzke EDSS score of 0-5.5.&#xD;
&#xD;
          3. Subjects must be in a stable neurological condition and free of corticosteroid&#xD;
             treatment [intravenous (iv), intramuscular (im) and/or per os (po)] 30 days prior to&#xD;
             screening (month -1).&#xD;
&#xD;
          4. Subjects must have had experienced one of the following:&#xD;
&#xD;
               -  At least one documented relapse in the 12 months prior to screening&#xD;
&#xD;
               -  At least two documented relapses in the 24 months prior to screening&#xD;
&#xD;
               -  One documented relapse between 12 and 24 months prior to screening with at least&#xD;
                  one documented T1-Gd enhancing lesion in an MRI performed within 12 months prior&#xD;
                  to screening.&#xD;
&#xD;
          5. Subjects must be between 18 and 55 years of age, inclusive.&#xD;
&#xD;
          6. Subjects must have disease duration of at least 6 months (from the first symptom)&#xD;
             prior to screening.&#xD;
&#xD;
          7. Women of child-bearing potential must practice an acceptable method of birth control&#xD;
             [acceptable methods of birth control in this study include: surgical sterilization,&#xD;
             intrauterine devices, oral contraceptive, contraceptive patch, long-acting injectable&#xD;
             contraceptive, partner's vasectomy or double-barrier method (condom or diaphragm with&#xD;
             spermicide).&#xD;
&#xD;
          8. Subjects must be able to sign and date a written informed consent prior to entering&#xD;
             the study&#xD;
&#xD;
          9. Subjects must be willing and able to comply with the protocol requirements for the&#xD;
             duration of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with progressive forms of MS&#xD;
&#xD;
          2. An onset of relapse, unstable neurological condition or any treatment with&#xD;
             corticosteroids [intravenous (iv), intramuscular (im) and/or per os (po)] or ACTH&#xD;
             between month -1 (screening) and 0 (baseline).&#xD;
&#xD;
          3. Use of experimental or investigational drugs, and/or participation in drug clinical&#xD;
             studies within the 6 months prior to screening.&#xD;
&#xD;
          4. Use of immunosuppressive including Mitoxantrone (NovantroneÂ®) or cytotoxic agents&#xD;
             within 6 months prior to the screening visit.&#xD;
&#xD;
          5. Previous use of either of the following: natalizumab (TysabriÂ®), cladribine,&#xD;
             laquinimod.&#xD;
&#xD;
          6. Previous treatment with glatiramer acetate (CopaxoneÂ®) Interferon-Î² (either 1a or 1b)&#xD;
             or IVIG within 2 months prior to screening visit.&#xD;
&#xD;
          7. Systemic corticosteroid treatment of â¥30 consecutive days duration within 2 months&#xD;
             prior to screening visit.&#xD;
&#xD;
          8. Previous total body irradiation or total lymphoid irradiation.&#xD;
&#xD;
          9. Previous stem cell treatment, autologous bone marrow transplantation or allogenic bone&#xD;
             marrow transplantation.&#xD;
&#xD;
         10. A known history of tuberculosis.&#xD;
&#xD;
         11. Acute infection two weeks prior to baseline visit.&#xD;
&#xD;
         12. Major trauma or surgery two weeks prior to baseline&#xD;
&#xD;
         13. A history of vascular thrombosis (excluding catheter-site superficial venous&#xD;
             thrombophlebitis).&#xD;
&#xD;
         14. A carrier state of factor V Leiden mutation (either homo- or heterozygous) as&#xD;
             disclosed at screening.&#xD;
&#xD;
         15. Positive screening test for Hepatitis B surface antigen, Hepatitis C antibody, or HIV&#xD;
             antibody as disclosed at screening visit.&#xD;
&#xD;
         16. Use of potent inhibitors of CYP3A4 within 2 weeks prior to baseline visit (1 month for&#xD;
             fluoxetine) see detailed list in Appendix 5&#xD;
&#xD;
         17. Use of amiodarone within 2 years prior to screening visit.&#xD;
&#xD;
         18. Pregnancy or breastfeeding.&#xD;
&#xD;
         19. Subjects with a clinically significant or unstable medical or surgical condition that&#xD;
             would preclude safe and complete study participation, as determined by medical&#xD;
             history, physical examinations, ECG, laboratory tests or chest X-ray. Such conditions&#xD;
             may include:&#xD;
&#xD;
               -  A cardiovascular or pulmonary disorder that cannot be well-controlled by standard&#xD;
                  treatment permitted by the study protocol.&#xD;
&#xD;
               -  A gastrointestinal disorder that may affect the absorption of study medication.&#xD;
&#xD;
               -  Renal or metabolic diseases.&#xD;
&#xD;
               -  Any form of chronic liver disease, including known non-alcoholic steatohepatitis.&#xD;
&#xD;
               -  A â¥2xULN serum elevation of either of the following at screening: ALT, AST or&#xD;
                  direct bilirubin&#xD;
&#xD;
               -  A QTC interval (obtained from either 2 ECG recordings at screening or from the&#xD;
                  mean value calculated from 3 measurements at baseline visit) which is &gt;450msec.&#xD;
&#xD;
               -  A family history of Long- QT syndrome.&#xD;
&#xD;
               -  A history of drug and/or alcohol abuse.&#xD;
&#xD;
               -  Major psychiatric disorder.&#xD;
&#xD;
         20. A known history of sensitivity to Gd.&#xD;
&#xD;
         21. Inability to successfully undergo MRI scanning.&#xD;
&#xD;
         22. Known drug hypersensitivity that would preclude administration of laquinimod, such as&#xD;
             hypersensitivity to: mannitol, meglumine or sodium stearyl fumarate.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects who suffer from any form of progressive MS.&#xD;
&#xD;
          2. Any condition which the investigator feels may interfere with participation in the&#xD;
             study.&#xD;
&#xD;
          3. Subjects with a clinically significant or unstable medical or surgical condition that&#xD;
             would preclude safe and complete study participation,&#xD;
&#xD;
          4. Subjects who received any investigational medication, immunosuppressives or cytotoxic&#xD;
             agents within 6 months prior to screening&#xD;
&#xD;
          5. Previous treatment with immunomodulators within two months prior to screening&#xD;
&#xD;
          6. Pregnancy or breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giancarlo Comi</last_name>
    <role>Principal Investigator</role>
    <affiliation>U.O.Neurology-Neurorehabilitation and Clinical Neurophysiology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Teva Investigational Site 1076</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1090</name>
      <address>
        <city>Centennial</city>
        <state>Colorado</state>
        <zip>80112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1088</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <zip>80528</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1094</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520-8018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1102</name>
      <address>
        <city>Northbrook</city>
        <state>Illinois</state>
        <zip>60062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1081</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1083</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50314</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1086</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1101</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40513</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1096</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1093</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1098</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1082</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1079</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1073</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1097</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1084</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45417</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1092</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1100</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033-0850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1087</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1075</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1078</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1085</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3300</name>
      <address>
        <city>Klagenfurt</city>
        <zip>9020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3303</name>
      <address>
        <city>Linz</city>
        <zip>A-4021</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3302</name>
      <address>
        <city>Sankt Polten</city>
        <zip>3100</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3301</name>
      <address>
        <city>Villach</city>
        <zip>9500</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5901</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5904</name>
      <address>
        <city>Sofia</city>
        <zip>1113</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5903</name>
      <address>
        <city>Sofia</city>
        <zip>1309</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5900</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5905</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5902</name>
      <address>
        <city>Varna</city>
        <zip>9010</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1132</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3M 0A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1126</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1128</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K2G 6E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1134</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1130</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <zip>J4V 2J2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1129</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1131</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5417</name>
      <address>
        <city>Olomouc</city>
        <zip>779 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5416</name>
      <address>
        <city>Ostrava - poruba</city>
        <zip>708 52</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5504</name>
      <address>
        <city>Tallinn</city>
        <zip>EE-10617</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5505</name>
      <address>
        <city>Tartu</city>
        <zip>EE-51014</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3525</name>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3527</name>
      <address>
        <city>Bron Cedex</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3526</name>
      <address>
        <city>Clermont-Ferrand Cedex 1</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3524</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3528</name>
      <address>
        <city>Marseille Cedex 5</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3529</name>
      <address>
        <city>Rennes Cedex 9</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 8100</name>
      <address>
        <city>Tbilisi</city>
        <zip>0112</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 8101</name>
      <address>
        <city>Tbilisi</city>
        <zip>0179</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3247</name>
      <address>
        <city>Bayreuth</city>
        <zip>95445</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3241</name>
      <address>
        <city>Berlin</city>
        <zip>10713</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3238</name>
      <address>
        <city>Berlin</city>
        <zip>13347</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3248</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3245</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3237</name>
      <address>
        <city>Emden</city>
        <zip>26721</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3242</name>
      <address>
        <city>Erbach</city>
        <zip>64711</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3240</name>
      <address>
        <city>Erfurt</city>
        <zip>99089</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3249</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3236</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3246</name>
      <address>
        <city>Hamburg</city>
        <zip>22417</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3239</name>
      <address>
        <city>Hannover</city>
        <zip>30559</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3243</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3251</name>
      <address>
        <city>Munster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3250</name>
      <address>
        <city>Trier</city>
        <zip>54292</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3244</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5115</name>
      <address>
        <city>Budapest</city>
        <zip>H-1145</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5114</name>
      <address>
        <city>Debrecen</city>
        <zip>4043</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5116</name>
      <address>
        <city>Miskolc</city>
        <zip>3526</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5117</name>
      <address>
        <city>Veszprem</city>
        <zip>H-8200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 8034</name>
      <address>
        <city>Haifa</city>
        <zip>31048</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 8031</name>
      <address>
        <city>Haifa</city>
        <zip>3436212</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 8030</name>
      <address>
        <city>Jerusalem</city>
        <zip>9112001</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 8033</name>
      <address>
        <city>Ramat Gan</city>
        <zip>5262160</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 8032</name>
      <address>
        <city>Tel Aviv</city>
        <zip>78278</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3044</name>
      <address>
        <city>Catania</city>
        <zip>95122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3045</name>
      <address>
        <city>Fidenza</city>
        <zip>43036</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3042</name>
      <address>
        <city>Gallarate</city>
        <zip>21013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3046</name>
      <address>
        <city>Grosseto</city>
        <zip>58100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3047</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3038</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 555</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3039</name>
      <address>
        <city>Milano</city>
        <zip>20148</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3041</name>
      <address>
        <city>Palermo</city>
        <zip>90146</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3040</name>
      <address>
        <city>Rome</city>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5604</name>
      <address>
        <city>Riga</city>
        <zip>1015</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5704</name>
      <address>
        <city>Kaunas</city>
        <zip>50009</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5705</name>
      <address>
        <city>Siauliai</city>
        <zip>76231</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3809</name>
      <address>
        <city>Groesbeek</city>
        <zip>6561 KE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3810</name>
      <address>
        <city>Nieuwegein</city>
        <zip>3430 EM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3811</name>
      <address>
        <city>Tilburg</city>
        <zip>5022 GC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5322</name>
      <address>
        <city>Czestochowa</city>
        <zip>42-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5320</name>
      <address>
        <city>Gorzow Wielkopolski</city>
        <zip>66-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5316</name>
      <address>
        <city>Katowice</city>
        <zip>40-752</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5318</name>
      <address>
        <city>Kielce</city>
        <zip>25-736</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5319</name>
      <address>
        <city>Konskie</city>
        <zip>26-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5317</name>
      <address>
        <city>Krakow</city>
        <zip>31-826</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5315</name>
      <address>
        <city>Lodz</city>
        <zip>90-153</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5325</name>
      <address>
        <city>Warszawa</city>
        <zip>04-749</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5208</name>
      <address>
        <city>Bucharest</city>
        <zip>011461</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5210</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400437</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5212</name>
      <address>
        <city>Constanta</city>
        <zip>900123</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5211</name>
      <address>
        <city>Targu-Mures</city>
        <zip>540136</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5209</name>
      <address>
        <city>Timisoara</city>
        <zip>300736</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5029</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620102</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5031</name>
      <address>
        <city>Kemerovo</city>
        <zip>650066</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5021</name>
      <address>
        <city>Moscow</city>
        <zip>127018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5028</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603126</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5027</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630087</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5030</name>
      <address>
        <city>Perm</city>
        <zip>614990</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5022</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5026</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>191025</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5025</name>
      <address>
        <city>St. Petersburg</city>
        <zip>194044</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5024</name>
      <address>
        <city>St. Petersburg</city>
        <zip>194354</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5023</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197376</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 6100</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 6102</name>
      <address>
        <city>Nis</city>
        <zip>18 000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3132</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3134</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3144</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3140</name>
      <address>
        <city>Beade-Vigo</city>
        <zip>36312</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3142</name>
      <address>
        <city>Getafe</city>
        <zip>28905</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3136</name>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3135</name>
      <address>
        <city>Lleida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3133</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3146</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3137</name>
      <address>
        <city>Murcia</city>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3138</name>
      <address>
        <city>Pontevedra</city>
        <zip>36001</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3139</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3143</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 4204</name>
      <address>
        <city>Stockholm</city>
        <zip>14186</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 4205</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 4206</name>
      <address>
        <city>Stockholm</city>
        <zip>18288</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 8201</name>
      <address>
        <city>Izmir</city>
        <zip>35340</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5803</name>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49027</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5802</name>
      <address>
        <city>Kyiv</city>
        <zip>03110</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5804</name>
      <address>
        <city>Kyiv</city>
        <zip>03115</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5800</name>
      <address>
        <city>Lviv</city>
        <zip>79010</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5801</name>
      <address>
        <city>Vinnytsya</city>
        <zip>21005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3425</name>
      <address>
        <city>Liverpool</city>
        <zip>L9 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3424</name>
      <address>
        <city>London</city>
        <zip>E1 2AT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3422</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2JF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Georgia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>Former Serbia and Montenegro</country>
    <country>Portugal</country>
  </removed_countries>
  <link>
    <url>http://www.TevaClinicalTrials.com/patients/default.aspx</url>
    <description>Teva's Allegro Clinical Trials website</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 27, 2007</study_first_submitted>
  <study_first_submitted_qc>July 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2007</study_first_posted>
  <results_first_submitted>July 8, 2021</results_first_submitted>
  <results_first_submitted_qc>October 5, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">November 2, 2021</results_first_posted>
  <disposition_first_submitted>February 16, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>February 16, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 20, 2012</disposition_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relapsing</keyword>
  <keyword>Remitting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>1106 participants were enrolled and randomized in the placebo-controlled (PC) double-blind period. Participants were randomized 1:1 to the treatment arms.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Laquinimod</title>
          <description>Laquinimod 0.6 mg capsule taken orally once a day</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Matching placebo capsule taken orally once a day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="550"/>
                <participants group_id="P2" count="556"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="437"/>
                <participants group_id="P2" count="427"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="113"/>
                <participants group_id="P2" count="129"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by participant after confirmed relapse</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent to treat (ITT) analysis set included all participants that were randomized.</population>
      <group_list>
        <group group_id="B1">
          <title>Laquinimod</title>
          <description>Laquinimod 0.6 mg capsule taken orally once a day</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Matching placebo capsule taken orally once a day</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="550"/>
            <count group_id="B2" value="556"/>
            <count group_id="B3" value="1106"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="550"/>
                    <count group_id="B2" value="556"/>
                    <count group_id="B3" value="1106"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.9" spread="9.2"/>
                    <measurement group_id="B2" value="38.5" spread="9.1"/>
                    <measurement group_id="B3" value="38.7" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="550"/>
                    <count group_id="B2" value="556"/>
                    <count group_id="B3" value="1106"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="391"/>
                    <measurement group_id="B2" value="368"/>
                    <measurement group_id="B3" value="759"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="159"/>
                    <measurement group_id="B2" value="188"/>
                    <measurement group_id="B3" value="347"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <population>Race not reported for 4 participants.</population>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Race : Asian</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="548"/>
                    <count group_id="B2" value="554"/>
                    <count group_id="B3" value="1102"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Race : Black or African American</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="548"/>
                    <count group_id="B2" value="554"/>
                    <count group_id="B3" value="1102"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Race : White</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="548"/>
                    <count group_id="B2" value="554"/>
                    <count group_id="B3" value="1102"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="532"/>
                    <measurement group_id="B2" value="532"/>
                    <measurement group_id="B3" value="1064"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Race : Hispanic</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="548"/>
                    <count group_id="B2" value="554"/>
                    <count group_id="B3" value="1102"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Race : Other</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="548"/>
                    <count group_id="B2" value="554"/>
                    <count group_id="B3" value="1102"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Relapse Rate: Number of Confirmed Relapses During the Double Blind Study Period</title>
        <description>A relapse was defined as the appearance of at least one new neurological abnormality or the reappearance of at least one previously observed neurological abnormalities lasting greater than or equal to 48 hours and immediately preceded by an improving neurological state of greater than or equal to 30 days from onset of previous relapse. An event was counted as a relapse only when the participant's symptoms were accompanied by observed objective neurological changes, consistent with one or more of the following: An increase of greater than or equal to 0.5 in the Expanded Disability Status Scale (EDSS) score as compared to previous evaluation, an increase of one grade in the actual score of greater than or equal to 2 of the 7 functional systems (FS), as compared to previous evaluation, or an increase of 2 grades in the actual score of one FS as compared to the previous evaluation.</description>
        <time_frame>Up to Month 24</time_frame>
        <population>Intent to treat (ITT) analysis set included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Laquinimod</title>
            <description>Laquinimod 0.6 mg capsule taken orally once a day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo capsule taken orally once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Relapse Rate: Number of Confirmed Relapses During the Double Blind Study Period</title>
          <description>A relapse was defined as the appearance of at least one new neurological abnormality or the reappearance of at least one previously observed neurological abnormalities lasting greater than or equal to 48 hours and immediately preceded by an improving neurological state of greater than or equal to 30 days from onset of previous relapse. An event was counted as a relapse only when the participant's symptoms were accompanied by observed objective neurological changes, consistent with one or more of the following: An increase of greater than or equal to 0.5 in the Expanded Disability Status Scale (EDSS) score as compared to previous evaluation, an increase of one grade in the actual score of greater than or equal to 2 of the 7 functional systems (FS), as compared to previous evaluation, or an increase of 2 grades in the actual score of one FS as compared to the previous evaluation.</description>
          <population>Intent to treat (ITT) analysis set included all randomized participants.</population>
          <units>Confirmed relapses</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="550"/>
                <count group_id="O2" value="556"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.54" spread="0.88"/>
                    <measurement group_id="O2" value="0.67" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Response variable: number of relapses during 24 months. Offset based on the log of subject's exposure in years was employed to adjust for variability of treatment exposure. In addition to the treatment group, the Poisson regression model included the following covariates: baseline EDSS score, log of prior 2-year number of relapses+1 and Country or Geographical Region (CGR).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0024</p_value>
            <method>Over-dispersed Poisson Regression</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.770</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.066</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.650</ci_lower_limit>
            <ci_upper_limit>0.911</ci_upper_limit>
            <estimate_desc>Laquinimod 0.6 mg vs. placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite Endpoint: Sum of the Number of T1 Gadolinium (Gd)-Enhanced Lesions on T1-Weighted MRI Images</title>
        <description>Composite score was calculated as the sum of the number of gadolinium (Gd)-enhanced lesions at Month 12 and the number of gadolinium (Gd)-enhanced lesions at Month 24 on T1-Weighted MRI scans.</description>
        <time_frame>Month 12, Month 24</time_frame>
        <population>ITT analysis set included all randomized participants. Number of participants analyzed included the number of participants evaluable at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Laquinimod</title>
            <description>Laquinimod 0.6 mg capsule taken orally once a day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo capsule taken orally once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Endpoint: Sum of the Number of T1 Gadolinium (Gd)-Enhanced Lesions on T1-Weighted MRI Images</title>
          <description>Composite score was calculated as the sum of the number of gadolinium (Gd)-enhanced lesions at Month 12 and the number of gadolinium (Gd)-enhanced lesions at Month 24 on T1-Weighted MRI scans.</description>
          <population>ITT analysis set included all randomized participants. Number of participants analyzed included the number of participants evaluable at each time point.</population>
          <units>Lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="482"/>
                <count group_id="O2" value="464"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.86" spread="5.02"/>
                    <measurement group_id="O2" value="2.92" spread="7.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite Endpoint: Sum of the Number of New/Enlarging T2 Lesions</title>
        <description>Composite score calculated as the sum of T2 lesions at Months 12 and 24 that are new or enlarged.</description>
        <time_frame>Month 12, Month 24</time_frame>
        <population>ITT analysis set included all randomized participants. Number of participants analyzed included the number of participants evaluable at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Laquinimod</title>
            <description>Laquinimod 0.6 mg capsule taken orally once a day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo capsule taken orally once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Endpoint: Sum of the Number of New/Enlarging T2 Lesions</title>
          <description>Composite score calculated as the sum of T2 lesions at Months 12 and 24 that are new or enlarged.</description>
          <population>ITT analysis set included all randomized participants. Number of participants analyzed included the number of participants evaluable at each time point.</population>
          <units>Lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="482"/>
                <count group_id="O2" value="464"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.26" spread="9.08"/>
                    <measurement group_id="O2" value="7.87" spread="12.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Accumulation of Physical Disability Measured by the Time to Confirmed Progression of Expanded Disability Status Scale (EDSS)</title>
        <description>EDSS assesses disability in 8 functional systems with an overall score ranging from 0 (normal) to 10 (death due to multiple sclerosis [MS]). A confirmed progression of EDSS is defined as at least 1 point increase from baseline if baseline EDSS was between 0 and 5.0, or at least 0.5 point increase if baseline EDSS was 5.5 or higher, confirmed 3 months later. Participants were assessed between baseline and month 24 visit. Participants that met these criteria for any 3 consecutive months were counted in the progression category. Progression could not be confirmed during an MS relapse. Data is presented as a distribution of confirmed disease progression (CDP) events (number of participants with CDP).</description>
        <time_frame>Baseline to Month 24</time_frame>
        <population>ITT analysis set included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Laquinimod</title>
            <description>Laquinimod 0.6 mg capsule taken orally once a day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo capsule taken orally once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Accumulation of Physical Disability Measured by the Time to Confirmed Progression of Expanded Disability Status Scale (EDSS)</title>
          <description>EDSS assesses disability in 8 functional systems with an overall score ranging from 0 (normal) to 10 (death due to multiple sclerosis [MS]). A confirmed progression of EDSS is defined as at least 1 point increase from baseline if baseline EDSS was between 0 and 5.0, or at least 0.5 point increase if baseline EDSS was 5.5 or higher, confirmed 3 months later. Participants were assessed between baseline and month 24 visit. Participants that met these criteria for any 3 consecutive months were counted in the progression category. Progression could not be confirmed during an MS relapse. Data is presented as a distribution of confirmed disease progression (CDP) events (number of participants with CDP).</description>
          <population>ITT analysis set included all randomized participants.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="550"/>
                <count group_id="O2" value="556"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Progressed</title>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="78"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Progression Free</title>
                  <measurement_list>
                    <measurement group_id="O1" value="496"/>
                    <measurement group_id="O2" value="478"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Disability as Assessed by the Multiple Sclerosis Functional Composite (MSFC) Score</title>
        <description>The Multiple Sclerosis Functional Composite is an instrument assessing disability that consists of 3 clinical assessments. The 3 are Timed 25-Foot Walk, 9-Hole Peg Test which measures upper extremity (arm and hand) function, and PASAT (Paced Auditory Serial Addition Test) which is a measure of cognitive function that specifically assesses auditory information processing speed and flexibility, as well as calculation ability. A Z-score is used to define a common metric from the 3 assessments that constitute the MSFC score. The study's population at baseline was used as reference population for the Z-score calculation. A Z-score of 0 represents the population mean at baseline. Higher Z-scores correspond to an improved outcome.</description>
        <time_frame>Baseline, Month 24</time_frame>
        <population>ITT analysis set included all randomized participants. Number of participants analyzed included the number of participants evaluable at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Laquinimod</title>
            <description>Laquinimod 0.6 mg capsule taken orally once a day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo capsule taken orally once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Disability as Assessed by the Multiple Sclerosis Functional Composite (MSFC) Score</title>
          <description>The Multiple Sclerosis Functional Composite is an instrument assessing disability that consists of 3 clinical assessments. The 3 are Timed 25-Foot Walk, 9-Hole Peg Test which measures upper extremity (arm and hand) function, and PASAT (Paced Auditory Serial Addition Test) which is a measure of cognitive function that specifically assesses auditory information processing speed and flexibility, as well as calculation ability. A Z-score is used to define a common metric from the 3 assessments that constitute the MSFC score. The study's population at baseline was used as reference population for the Z-score calculation. A Z-score of 0 represents the population mean at baseline. Higher Z-scores correspond to an improved outcome.</description>
          <population>ITT analysis set included all randomized participants. Number of participants analyzed included the number of participants evaluable at each time point.</population>
          <units>Z score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="424"/>
                <count group_id="O2" value="420"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.4"/>
                    <measurement group_id="O2" value="0.0" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline to 24 months</time_frame>
      <desc>Safety analysis included all participants that received at least one dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Laquinimod 0.6 mg</title>
          <description>Laquinimod 0.6 mg capsule taken orally once a day</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Matching placebo capsule taken orally once a day</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (13.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="556"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Uveitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="556"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Anal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Gastroduodenitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Drug interaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Nodule</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Drug-induced liver injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="556"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="550"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Vestibular neuronitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Infectious colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Infectious mononucleosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Staphylococcal pharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Vaginitis bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Bacterial test positive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Folate deficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Intraductal proliferative breast lesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Ovarian adenoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="550"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Breast cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Cholesteatoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Glioblastoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Oesophageal adenocarcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Ovarian granulosa-theca cell tumour</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="556"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cervicobrachial syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis relapse</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="550"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Dyskinesia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Lumbosacral radiculopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion threatened</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Adjustment disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Delusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Hallucination, auditory</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Hallucination, visual</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="556"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Endometrial hyperplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Menometrorrhagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Breast haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Cervical cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Fallopian tube cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Ovarian adhesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Ovarian cyst ruptured</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Uterine cervical squamous metaplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="556"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cholecystectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Hysterectomy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="550"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Spinal fusion surgery</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Abortion induced</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Anorectal operation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Appendicectomy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Bone graft</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Bone operation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Cholesteatoma removal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Chondroplasty</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Cyst drainage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Ligament operation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Mastectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Meniscus removal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Plasmapheresis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Rehabilitation therapy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Renal stone removal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Spinal decompression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Spinal laminectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Turbinectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Uterine dilation and curettage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Phlebitis superficial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis superficial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Vein disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="556"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (13.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="368" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="346" subjects_at_risk="556"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="33" subjects_affected="28" subjects_at_risk="550"/>
                <counts group_id="E2" events="34" subjects_affected="29" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="49" subjects_affected="42" subjects_at_risk="550"/>
                <counts group_id="E2" events="41" subjects_affected="33" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="38" subjects_affected="34" subjects_at_risk="550"/>
                <counts group_id="E2" events="38" subjects_affected="32" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="36" subjects_affected="31" subjects_at_risk="550"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="556"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="28" subjects_affected="25" subjects_at_risk="550"/>
                <counts group_id="E2" events="36" subjects_affected="29" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="21" subjects_affected="20" subjects_at_risk="550"/>
                <counts group_id="E2" events="34" subjects_affected="28" subjects_at_risk="556"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="39" subjects_affected="33" subjects_at_risk="550"/>
                <counts group_id="E2" events="50" subjects_affected="44" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="159" subjects_affected="100" subjects_at_risk="550"/>
                <counts group_id="E2" events="199" subjects_affected="119" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="40" subjects_affected="29" subjects_at_risk="550"/>
                <counts group_id="E2" events="38" subjects_affected="25" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="61" subjects_affected="42" subjects_at_risk="550"/>
                <counts group_id="E2" events="62" subjects_affected="48" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="60" subjects_affected="40" subjects_at_risk="550"/>
                <counts group_id="E2" events="35" subjects_affected="24" subjects_at_risk="556"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="49" subjects_affected="38" subjects_at_risk="550"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="556"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="61" subjects_affected="47" subjects_at_risk="550"/>
                <counts group_id="E2" events="51" subjects_affected="41" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="122" subjects_affected="89" subjects_at_risk="550"/>
                <counts group_id="E2" events="73" subjects_affected="50" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="47" subjects_affected="35" subjects_at_risk="550"/>
                <counts group_id="E2" events="44" subjects_affected="38" subjects_at_risk="556"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="225" subjects_affected="123" subjects_at_risk="550"/>
                <counts group_id="E2" events="176" subjects_affected="99" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="29" subjects_affected="27" subjects_at_risk="550"/>
                <counts group_id="E2" events="33" subjects_affected="29" subjects_at_risk="556"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="31" subjects_affected="30" subjects_at_risk="550"/>
                <counts group_id="E2" events="32" subjects_affected="32" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="40" subjects_affected="36" subjects_at_risk="550"/>
                <counts group_id="E2" events="39" subjects_affected="31" subjects_at_risk="556"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="47" subjects_affected="40" subjects_at_risk="550"/>
                <counts group_id="E2" events="29" subjects_affected="25" subjects_at_risk="556"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="24" subjects_affected="23" subjects_at_risk="550"/>
                <counts group_id="E2" events="34" subjects_affected="29" subjects_at_risk="556"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director, Clinical Research</name_or_title>
      <organization>Teva Branded Pharmaceutical Products R&amp;D, Inc.</organization>
      <phone>1-888-483-8279</phone>
      <email>USMedInfo@tevapharm.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

